NCT05655299 (Serenity PsO) is a Phase 2 clinical trial of VTX958 Dose A in Psoriasis, sponsored by Ventyx Biosciences, Inc.

Who is sponsoring NCT05655299?

NCT05655299 is sponsored by Ventyx Biosciences, Inc.

What drugs are being tested in NCT05655299?

Interventions in NCT05655299: VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, Placebo.

Is NCT05655299 still recruiting?

NCT05655299 is currently terminated. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT05655299: Serenity PsO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

Terminated Phase 2 Last updated 19 September 2024

What this trial tests

Phase 2 trial testing VTX958 Dose A in Psoriasis in 222 participants. Terminated before completion.

Timeline

17 November 2022

Primary endpoint
25 September 2023

20 December 2023

Quick facts

Lead sponsor	Ventyx Biosciences, Inc
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	222
Start date	17 November 2022
Primary completion	25 September 2023
Estimated completion	20 December 2023
Sites	63 locations across Canada, United States, Poland

Drugs / interventions tested

VTX958 Dose A — full drug profile →
VTX958 Dose B — full drug profile →
VTX958 Dose C — full drug profile →
VTX958 Dose D — full drug profile →
Placebo

Conditions studied

Psoriasis — all drugs for Psoriasis →

Sponsor

Ventyx Biosciences, Inc — full company profile →

Who can join

18 and older, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a study to understand if taking VTX958 is safe and effective in participants diagnosed with moderate to severe psoriasis (PsO). Approximately 200 patients will take VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, or placebo. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 16-week double-blind period (a participant receives active Dose A, Dose B, Dose C, Dose D, or placebo), a 16-week Long Term Extension (LTE) period, a 36-week Open Label Extension (OLE) period and a 4-week Follow-Up Period. The maximal duration of treatment will be approximately 16 months.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors.
Jensen LT, Attfield KE, Feldmann M, Fugger L. · · 2023 · cited 45× · PMID 37863021 · DOI 10.1016/j.ebiom.2023.104840
New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis.
Carmona-Rocha E, Rusiñol L, Puig L. · · 2024 · cited 28× · PMID 38399292 · DOI 10.3390/pharmaceutics16020239

Verify or expand the search:

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Other Ventyx Biosciences, Inc trials

Trials by the same sponsor.

NCT05715125 — VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA) · Phase 2 · terminated
NCT05688852 — VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05655299 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ventyx Biosciences, Inc
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05655299.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing